Company to present on its Bispecifics
Heterodimer Assay and Custom Productivity Assay for the
Opto® Cell Line Development workflow
GSK Vaccines, Rockville to present on their successful
implementation of the Berkeley Lights'
Beacon® technology for accelerated cell
line development for complex subunit vaccine candidates
EMERYVILLE, Calif., Sept. 21,
2022 /PRNewswire/ -- Berkeley Lights, Inc. (Nasdaq:
BLI), a leader in digital cell biology, today announced its
participation at the Bioprocess International 2022 Conference
(BPI) being held from September 27 -
30, 2022, at the Boston Convention and Exhibition Center.
The BPI Conference is one of the largest bioprocessing events for
learning how to accelerate promising biologics, cell, and gene
therapies towards commercial success.
At the conference, Berkeley Lights will feature its Beacon®
optofluidic platform technology and workflows in booth #830.
Attendees will have a chance to explore hands-on demonstrations of
the technology as well as how to apply the Berkeley Lights Custom
Productivity Assay for cell line development (CLD) to rapidly
select clones that are producing high-quality bispecific
molecules.
Berkeley Lights is also a sponsor of the BPI 2022 Scientific
Track Presentation. Aurora
Fabry-Wood, Ph.D., product manager, Cell Line Development at
Berkeley Lights is scheduled to present on Wednesday, September
28 at 9:30 a.m. ET in room 210C
associated with the Cell Culture track.
Presentation Title: Go Beyond Titer and Select Top Producers
with Favorable Quality Attributes within 5 days of
Cloning
Presentation Abstract: Despite a growing need for earlier
information on quality and manufacturability, initial clone
screening in mammalian cell line development (CLD) continues to
focus on selection for growth and titer. Yet the fastest-growing
and highest-producing clones may not secrete a product with the
appropriate quality attributes. As a consequence, large numbers of
clones must be expanded and characterized through repeated rounds
of selection in order to maximize the probability of finding a cell
line that makes high titers of manufacturable product. The Berkeley
Lights Opto® CLD workflow on the Beacon® optofluidic system
accelerates early CLD by integrating high throughput cell sorting,
cloning, culture, productivity, growth, and product quality assays
into a single, five-day automated process. Come join us and
we will show you how to go beyond titer by selecting manufacturable
cell lines as early as possible.
On Tuesday, September 27 at
12:30 p.m. ET, Jishna Ganguly,
scientist in the CHO Mammalian Expression Technology Centre of
Excellence team within the drug substance group at GSK Vaccines,
Rockville will lead a presentation
titled: Implementing Beacon Optofluidic Technology for
Accelerated Cell Line Development for Complex Subunit Vaccine
Candidates.
Presentation Abstract: Under current regulatory
guidelines, CLD for complex multi-subunit protein-based vaccines
are resource and labor intensive. Beacon optofluidic system enables
automated high throughput single cell cloning and clone screening
based on multiple performance and quality attributes (e.g.,
clonality, cell growth and antigen epitope integrity). In the case
study, GSK Vaccines, Rockville
developed a novel Beacon CLD workflow for multiple complex antigens
and benchmarked it with a state of art FACS based approach. Based
on the result, it's confirmed that this novel strategy can be
readily implemented as a platform approach for accelerating CLD for
vaccine development.
Visit the Berkeley Lights website for more information on its
Cell Line Development workflow.
About Berkeley Lights
Berkeley Lights is a leading digital cell biology company
focused on enabling and accelerating the rapid development and
commercialization of biotherapeutics and other cell-based products
for our customers. The Berkeley Lights Platform captures deep
phenotypic, functional, and genotypic information for thousands of
single cells in parallel and can also deliver the live biology
customers desire in the form of the best cells. Our platform is a
fully integrated, end-to-end solution, comprised of proprietary
consumables, including our OptoSelect® chips and reagent kits,
advanced automation systems, and application software. We developed
the Berkeley Lights Platform to provide the most advanced
environment for rapid functional characterization of single cells
at scale, the goal of which is to establish an industry standard
for our customers throughout their cell-based product value
chain.
Forward-Looking Statements
To the extent that statements contained in this press release
are not descriptions of historical facts regarding Berkeley Lights
or its products, they are forward-looking statements reflecting the
current beliefs and expectations of management. Such
forward-looking statements involve substantial known and unknown
risks and uncertainties that relate to future events, and actual
results and product performance could differ significantly from
those expressed or implied by the forward-looking statements.
Berkeley Lights undertakes no obligation to update or revise any
forward-looking statements. For a further description of the risks
and uncertainties relating to the Company's growth and continual
evolution see the statements in the "Risk Factors" sections, and
elsewhere, in our filings with the U.S. Securities and Exchange
Commission.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/berkeley-lights-to-participate-in-the-bioprocess-international-2022-conference-301629627.html
SOURCE Berkeley Lights, Inc.